Genomics tool developer 10x Genomics has raised $35m that will be combined with the $50m SoftBank-backed first close it achieved in April.

Alexandria Real Estate Equities and Continental Grain Company have backed the first close of the Syngenta-backed agricultural bioprocessing platform's latest round.

Proceeds from the Alexandria Real Estate Equities-backed series B round will advance the company's development of progenitor cell-related medicines for hearing loss.

Novartis returned to reinvest in digital medicine developer Pear Therapeutics as part of a Temasek-led round that took its overall funding to more than $134m.

The series A funding will help UMass-founded genetic disease therapy developer Apic Bio progress targeted drugs for ALS and Alpha-1 antitrypsin deficiency.

Access Industries and SIG participated in a series C round that came three months after the auto parts marketplace raised $20m in series B funding.

Biontech, a spinout of Johannes Gutenberg University Mainz, has received $91.5m in funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

Schrödinger raised $85m from investors including WuXi AppTec and GV and will use the money to expand the capabilities of its drug discovery software.

Biontech has received $91.5m in equity funding as part of the extension of a deal to develop a cancer immunotherapy candidate with Sanofi.

The online pharmaceutical distributor has secured $73m in a series C-plus round that follows a Tencent-led round last April.